Maywufa (1731) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 美吾華

Maywufa (1731) reported revenue of NT$162.9 million for Oct 2026, +21.1% year on year and +14.5% from the previous month. Revenue for Jan–Oct 2026 was NT$1.44 billion (+10.5% year on year).

Year-on-year revenue growth: 14 months in a row. →

In Oct 2026, it ranked No. 51 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$120.7 million24/10Nov 2024 NT$128.4 millionDec 2024 NT$127 millionJan 2025 NT$179.8 millionFeb 2025 NT$123.2 million25/02Mar 2025 NT$119.4 millionApr 2025 NT$124.8 millionMay 2025 NT$121.2 millionJun 2025 NT$128.7 million25/06Jul 2025 NT$129.6 millionAug 2025 NT$113 millionSep 2025 NT$129.7 millionOct 2025 NT$134.6 million25/10Nov 2025 NT$134.6 millionDec 2025 NT$145.6 millionJan 2026 NT$187.2 millionFeb 2026 NT$127.7 million26/02Mar 2026 NT$137.4 millionApr 2026 NT$133.1 millionMay 2026 NT$137.1 millionJun 2026 NT$131.9 million26/06Jul 2026 NT$147.5 millionAug 2026 NT$133.2 millionSep 2026 NT$142.3 millionOct 2026 NT$162.9 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$162.9 million+21.1%+14.5%
Sep 2026NT$142.3 million+9.7%+6.8%
Aug 2026NT$133.2 million+18.0%-9.7%
Jul 2026NT$147.5 million+13.8%+11.8%
Jun 2026NT$131.9 million+2.5%-3.9%
May 2026NT$137.1 million+13.1%+3.0%
Apr 2026NT$133.1 million+6.7%-3.1%
Mar 2026NT$137.4 million+15.1%+7.6%
Feb 2026NT$127.7 million+3.7%-31.8%
Jan 2026NT$187.2 million+4.2%+28.6%
Dec 2025NT$145.6 million+14.7%+8.2%
Nov 2025NT$134.6 million+4.8%+0.1%
Oct 2025NT$134.6 million+11.5%+3.7%
Sep 2025NT$129.7 million+11.8%+14.8%
Aug 2025NT$113 million-3.7%-12.8%
Jul 2025NT$129.6 million+9.4%+0.7%
Jun 2025NT$128.7 million+8.4%+6.1%
May 2025NT$121.2 million+2.0%-2.9%
Apr 2025NT$124.8 million+10.6%+4.5%
Mar 2025NT$119.4 million+6.9%-3.1%
Feb 2025NT$123.2 million+9.3%-31.5%
Jan 2025NT$179.8 million-1.9%+41.6%
Dec 2024NT$127 million+9.0%-1.1%
Nov 2024NT$128.4 million+10.9%+6.4%
Oct 2024NT$120.7 million+15.5%+4.0%

Jan–Oct 2026 cumulative: NT$1.44 billion (+10.5% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Maywufa vs PEC / Maywufa vs Lotus Pharm / Maywufa vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

Company remark (original Chinese)

本期美髮新品上市深受歡迎,營收較去年同期大幅成長逾21%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16